NASDAQ:SCLN - SciClone Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$11.15 0.00 (0.00 %)
(As of 07/15/2018 04:00 PM ET)
Previous Close$11.15
Today's Range$11.15 - $11.15
52-Week Range$8.55 - $11.43
VolumeN/A
Average Volume444,833 shs
Market Capitalization$581.94 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
SciClone Pharmaceuticals logoSciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.

Receive SCLN News and Ratings via Email

Sign-up to receive the latest news and ratings for SCLN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNASDAQ:SCLN
CUSIP80862K10
Phone+1-650-3583456

Debt

Debt-to-Equity RatioN/A
Current Ratio8.36
Quick Ratio7.57

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins27.39%
Return on Equity20.24%
Return on Assets18.42%

Miscellaneous

Employees570
Outstanding Shares52,190,000
Market Cap$581.94

The Truth About Cryptocurrencies

SciClone Pharmaceuticals (NASDAQ:SCLN) Frequently Asked Questions

What is SciClone Pharmaceuticals' stock symbol?

SciClone Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCLN."

How were SciClone Pharmaceuticals' earnings last quarter?

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) released its earnings results on Tuesday, May, 10th. The specialty pharmaceutical company reported $0.19 earnings per share for the quarter. The specialty pharmaceutical company earned $36.50 million during the quarter, compared to analyst estimates of $33.60 million. SciClone Pharmaceuticals had a net margin of 27.39% and a return on equity of 20.24%. View SciClone Pharmaceuticals' Earnings History.

What is the consensus analysts' recommendation for SciClone Pharmaceuticals?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SciClone Pharmaceuticals in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are SciClone Pharmaceuticals' key executives?

SciClone Pharmaceuticals' management team includes the folowing people:
  • Jon S Saxe, Independent Chairman of the Board
  • Friedhelm Blobel Ph.D., President, Chief Executive Officer, Director
  • Wilson W. Cheung, Chief Financial Officer, Senior Vice President - Finance, Secretary
  • Hong Zhao, Chief Executive Officer - China Operations
  • Raymond Anthony Low CPA, Vice President - Finance, Controller
  • Lan Xie CPA, Vice President - Finance, China Chief Financial Officer
  • Nancy T. Chang Ph.D., Independent Director
  • Richard James Hawkins, Independent Director
  • Anthony Gregg Lapointe, Independent Director
  • Simon Li, Independent Director

Has SciClone Pharmaceuticals been receiving favorable news coverage?

Press coverage about SCLN stock has trended positive on Sunday, Accern Sentiment reports. Accern identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. SciClone Pharmaceuticals earned a news impact score of 0.28 on Accern's scale. They also gave media stories about the specialty pharmaceutical company an impact score of 45.74 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of SciClone Pharmaceuticals?

Shares of SCLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is SciClone Pharmaceuticals' stock price today?

One share of SCLN stock can currently be purchased for approximately $11.15.

How big of a company is SciClone Pharmaceuticals?

SciClone Pharmaceuticals has a market capitalization of $581.94 million. SciClone Pharmaceuticals employs 570 workers across the globe.

How can I contact SciClone Pharmaceuticals?

SciClone Pharmaceuticals' mailing address is 950 Tower Ln Ste 900, FOSTER CITY, CA 94404-2125, United States. The specialty pharmaceutical company can be reached via phone at +1-650-3583456.


MarketBeat Community Rating for SciClone Pharmaceuticals (NASDAQ SCLN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  154 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  274
MarketBeat's community ratings are surveys of what our community members think about SciClone Pharmaceuticals and other stocks. Vote "Outperform" if you believe SCLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/15/2018 by MarketBeat.com Staff

Featured Article: Earnings Per Share

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.